Sergio Cifuentes Canaval: Selective sentinel node biopsy in people over 70 years of age
Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT México, shared a post on LinkedIn about a paper by Ton Wang et al. published in JCO Clinical Cancer Informatics:
“Selective Sentinel Node Biopsy in People Over 70 Years of Age: Clinical and Pathological Risk Stratification
In which patients with breast cancer, +70 years of age, could we skip sentinel node biopsy?
High-Risk Groups (GC+ Risk >20%)
Clinical factors:
- cT2 tumors (except non-ductal/lobular histologies): >22%.
- cT1mi/a/b grade 3 tumors: 11.4%.
- Ductal/lobular cT2 + grade 2-3: 28.5%.
Pathological factors:
to. Lymphovascular invasion (LVI):
- pT1mi/a/b with LVI: 22.5%.
- pT3-T4 with LVI: up to 72.8%.
- pT2-T4 tumors without LVI: >18% (except non-ductal/lobular pT2: 2.7%).
b. Low Risk Groups (Risk GC+ <10%)
- Tumores cT1mi/a/b (no grado 3).
- Tumores pT1 sin LVI.
For my clinical practice:
The pathological model (AUC 0.78) was superior to the clinical one. This supports omitting the GC biopsy in low-risk patients (pT1 without LVI or cT1mi/a/b not grade 3), while in high-risk patients (cT2+, grade 3, or LVI+), lymph node study remains crucial.”
Authors: Ton Wang, Drew Neish, Samantha Thomas, Astrid Botty van den Bruele, Laura Rosenberger, Akiko Chiba, Kendra Modell Parrish, Maggie DiNome, Lesly Dossett, Charles Scales Jr, Leah Zullig, Shelley Hwang, Jennifer Plichta.
More posts featuring Sergio Cifuentes Canaval.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023